PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-31.05%
Both companies show declining cash positions (-31.05% vs CRVO's -14.81%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-31.05%
Cash + STI yoy ≥ 1.5x CRVO's -14.81%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
Higher Other Current Assets Growth compared to CRVO's zero value, indicating worse performance.
-31.37%
≥ 1.5x CRVO's -15.59%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
76.50%
Below half CRVO's -6.58%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.08%
Below half of CRVO's -25.94%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-30.47%
1.25-1.5x CRVO's -21.20%. Bruce Berkowitz sees a stronger asset build. Check if it's producing returns.
-21.72%
Similar yoy growth to CRVO's -26.58%. Walter Schloss sees parallel payables strategy. Check top-line correlation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.72%
Less than half of CRVO's 37.45%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.72%
Less than half of CRVO's 1.63%. David Dodd sees far fewer liability expansions relative to competitor.
0.01%
Higher Common Stock (Book Value) Growth compared to CRVO's zero value, indicating worse performance.
-3.53%
Below half CRVO's -9.94%. Michael Burry suspects major net losses or high dividends vs. competitor.
-5.52%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-33.13%
1.25-1.5x CRVO's -23.42%. Bruce Berkowitz notes an above-average equity expansion.
-30.47%
1.25-1.5x CRVO's -21.20%. Bruce Berkowitz checks if expansions are well-justified by ROI.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.05%
Above 1.5x CRVO's 14.81%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.